Amelanotic nodular malignant melanoma in a patient with a family history of skin cancers

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Amelanotic skin melanoma is the amelanotic or hypomelanotic subtype of nodular melanoma. Amelanotic melanoma accounts for almost 60% of completely unrecognized melanoma. Amelanototic melanomas may not have the classic features of other melanomas and are usually red or skin-colored and more symmetrical, so superficially spreading melanomas are more easily recognized by most healthcare professionals and even patients.

Today, the path of melanoma development associated with genetic predisposition is being considered, in particular, with an unfavorable oncological family history, which is characterized by the development of melanoma in areas of the body periodically exposed to insolation, such as the trunk and limbs. The mechanism underlying amelanosis is not fully understood. As in pigment analogs, amelanotic melanoma cells retain their melanin-producing ability due to the expression of tyrosinase and microphthalmia-associated transcription factor.

We present our own clinical case of the development of a rare amelanocytic nodular melanoma on the leg in a patient with a family history of cancer. The complexity of the presented clinical case lies in the clinical picture atypical for nodular melanoma, since the formation was not pigmented, which did not cause concern for the patient and doctors, since the clinical picture was more consistent with a typical pyogenic granuloma. The patient underwent a wide excision of the formation. Further examination ruled out tumor metastases. The patient received a course of prophylactic therapy with recombinant interferon alfa. There was no recurrence of the disease during 3 years of follow-up. No metastasis has been observed so far.

Full Text

Restricted Access

About the authors

Elena S. Snarskaya

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
ORCID iD: 0000-0002-7968-7663
SPIN-code: 3785-7859

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Olga Yu. Olisova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989

MD, Dr. Sci. (Med.), Professor, Corresponding Member Russian Academy of Sciences

Russian Federation, Moscow

Kseniya D. Vasileva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID iD: 0000-0001-8693-9622
SPIN-code: 5834-5044
Russian Federation, Moscow


  1. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, 2012. Available from: Accessed: 15.03.2022.
  2. Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003;95(11):806–812. doi: 10.1093/jnci/95.11.806
  3. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol. 2005;23(12):2669–2675. doi: 10.1200/JCO.2005.11.108
  4. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161–1171. doi: 10.1016/j.jid.2016.01.035
  5. Gershenwald JE, Scolyer RA, Hess KR, еt al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. doi: 10.3322/caac.21409
  6. Watts CG, Madronio C, Morton RL, еt al. Clinical features associated with individuals at higher risk of melanoma: a population-based study. JAMA Dermatol. 2017;153(1):23–29. doi: 10.1001/jamadermatol.2016.3327
  7. Khaled M, Levy C, Fisher DE. Control of melanocyte differentiation by a MIFT ― PDE4D3 homeostatic circuit. Genes Dev. 2010;24(20):2276–2281. doi: 10.1101/gad.1937710
  8. Cao J, Wan L, Hacker E, еt al. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013;51(4):409–422. doi: 10.1016/j.molcel.2013.08.010
  9. Shin TM, Etzkorn JR, Sobanko JF, еt al. Clinical factors associated with subclinical spread of in situ melanoma. J Am Acad Dermatol. 2017;76(4):707–713. doi: 10.1016/j.jaad.2016.10.049
  10. Crotty K, McCarty S, Mihm MC, еt al. The histological diagnosis and classification of melanoma. In: Textbook of melanoma: pathology, diagnosis and management 1st edition. Ed by J.F. Tompson, D.L. Morton, B.B.R. Kroon. London, New York; 2004. 704 р.
  11. Gong HZ, Zheng HY, Li J. Amelanotic melanoma. Melanoma Res. 2019;29(3):221–230. doi: 10.1097/CMR.0000000000000571
  12. Childs MD. Nonivasive cene expression testing in amelonotic melanoma. JAMA Dermatol. 2018;154(2):223–224. doi: 10.1001/jamadermatol.2017.4773
  13. Brown CK, Kirkwood JM. Medical management of melanoma. Surg Clin North Am. 2003;83(2):283–322, viii. doi: 10.1016/S0039-6109(02)00187-1

Supplementary files

Supplementary Files
1. Fig. 1. Patient K., 58 years old, nodular melanocytic melanoma of the skin.

Download (140KB)
2. Fig. 2. Cytological picture of melanoma (azur/eosin staining, ×200).

Download (306KB)
3. Fig. 3. Histological picture of melanoma (staining with hematoxylin and eosin, ×200).

Download (311KB)

Copyright (c) 2022 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 015912 от 28.03.1997 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies